Vectomega distribution deal
This article was originally published in The Tan Sheet
Executive Summary
New Chapter and EuroPharma have inked an agreement that appoints New Chapter as the exclusive distributor of the Green Bay, Wisc.-based ingredient supplier's Vectomega omega-3 phospholipid complex for the health food/natural product retail channel, the firms announce Sept. 8. The ingredient is a "natural marine complex" that is "50 times more absorbable across cellular membranes than other DHA/EPA products," according to EuroPharma (1"The Tan Sheet" July 17, 2006, p. 6). Vectomega delivers DHA and EPA in "their natural phospholipid form" without artificial modifications, a trait that fits with New Chapter's principle of providing whole-food products and supplements, the Brattleboro, Vt.-based manufacturer states. EuroPharma President Terry Lemerond and the principle scientists will promote the product with personal endorsements, "including public appearances at trade shows and industry events," and possible television and radio appearances, the firms state. Additional details about the agreement were not disclosed...
You may also be interested in...
R&D In Brief
Acetaminophen and ovarian cancer: A meta-analysis published in the July British Journal of Clinical Pharmacology "supports a protective association between acetaminophen use and ovarian cancer and provides evidence for a dose effect." However, the potential association between the drug and the disease "deserves further verification, since proof of chemoprevention would represent a major public health advance," Stefanos Bonovas, University of Athens, Greece, et al., state. Researchers analyzed eight studies (four case-control and four cohort studies) published between 1998 and 2004 and concluded that an inverse association exists between acetaminophen use and ovarian cancer risk. The association "was marginally significant assuming a random-effects model...but not statistically significant assuming a fixed-effects model"...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.